HRP20141237T1 - Derivati 4-(metilaminofenoksi)pirdin-3-ilbenzamida za lijeäśenje raka - Google Patents
Derivati 4-(metilaminofenoksi)pirdin-3-ilbenzamida za lijeäśenje raka Download PDFInfo
- Publication number
- HRP20141237T1 HRP20141237T1 HRP20141237AT HRP20141237T HRP20141237T1 HR P20141237 T1 HRP20141237 T1 HR P20141237T1 HR P20141237A T HRP20141237A T HR P20141237AT HR P20141237 T HRP20141237 T HR P20141237T HR P20141237 T1 HRP20141237 T1 HR P20141237T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenoxy
- methylamino
- pyridin
- benzamide
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (12)
1. Spoj, naznačen time da je predstavljen sljedećom općom formulom (1) ili njegove soli:
[image]
pri čemu R1 predstavlja atom halogena, C6 do C10 arilnu skupinu, C6 do C10 ariloksi skupinu ili ravnu ili razgrananu alkilnu skupinu koja ima 1 do 6 atoma ugljika, gdje alkilna skupina po izboru može biti supstituirana s jednim ili više atoma halogena;
R2 predstavlja atom vodika, atom halogena, ravnu ili razgrananu alkilnu skupinu koja ima 1 do 6 atoma ugljika ili ravnu ili razgrananu alkoksi skupinu koja ima 1 do 6 atoma ugljika; a
m predstavlja jedan cijeli broj od 1 do 3;
pod uvjetom da kada m predstavlja 2 ili 3, R1s su isti ili različiti.
2. Spoj u skladu s patentnim zahtjevom 1 ili njegova sol, naznačen time, da R2 predstavlja atom vodika.
3. Spoj u skladu s patentnim zahtjevom 1 ili njegova sol, naznačen time, da R2 predstavlja atom halogena.
4. Spoj u skladu s patentnim zahtjevom 1 ili njegova sol, naznačen time, da R2 predstavlja ravnu ili razgrananu alkilnu skupinu koja ima 1 do 6 ugljikovih atoma.
5. Spoj u skladu s patentnim zahtjevom 1 ili njegova sol, naznačen time, da R2 predstavlja ravnu ili razgrananu alkoksi skupinu koja ima 1 do 6 ugljikovih atoma.
6. Spoj u skladu s patentnim zahtjevom 1 ili njegova sol, naznačen time, da je odabran iz skupine koja se sastoji od:
N-{6-[2-fluoro-4-(metilamino)fenoksi]piridin-3-il}-4-fenoksibenzamida,
N-{6-[2-fluoro-4-(metilamino)fenoksi]piridin-3-il}bifenil-4-karboksamida,
N-{6-[2-fluoro-4-(metilamino)fenoksi]piridin-3-il}-4(trifluorometil)benzamida,
2-fluoro-N-{6-[2-fluoro-4-(metilamino)fenoksi]piridin-3-jl}-4-(trifluorometil)benzamida,
2,3,4-trifluoro-N-{6-[2-fluoro-4-(metilamino)fenoksi]piridin-3-il}benzamida,
N-{6-[2-metil-4-(metilamino)fenoksi]pindin-3-il}-4-fenoksibenzamida,
N-{6-[2-metil-4-(metilamino)fenoksi]piridin-3-il}bifenil-4-karboksamida,
N-{6-[2-metil-4-(metilamino)fenoksi]piridin-3-il}-4(trifluorometil)benzamida,
2-fluoro-N-{6-[2-metil-4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamida,
N-{6-[4-(metilamino)fenoksi]piridin-3-il}-4-fenoksibenzamid],
N-{6-[4-(metilamino)fenoksi]piridin-3-il}bifenil-4-karboksamida,
N-{6-[2-metoksi-4-(rnetilamino)fenoksijpiridin-3-il}-4-(trifluorometil)benzamida,
N-{6-[2-metoksi-4-(metilamino)fenoksi]piridin-3-il}-4-fenoksibenzamida,
N-{6-[2-metoksi-4-(metilamino)fenoksi]piridin-3-il}bifenil-4-karboksamida,
2-fluoro-N-{6-[2-metoksi-4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamida,
2,3,4-trifluoro-N-{6-[2-metoksi-4-(metilamino)fenoksi]piridin-3-il}benzamida,
2,3,4-trifluoro-N-{6-[2-metil-4-(metilamino)fenoksi]piridin-3-il}benzamida,
N-{6-[4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamida,
2-fluoro-N-{6-[4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamida, i
2,3,4-trifluoro-N-{6-[4-(metilamino)fenoksi]piridin-3-il}benzamida.
7. Spoj u skladu s patentnim zahtjevom 1 ili njegova sol, naznačen time, da je odabran iz skupine koja se sastoji od:
N-{6-[2-fluoro-4-(meti[amino)fenoksi]piridin-3-il}-4-fenoksibenzamida,
N-{6-[2-fluoro-4-(metilamino)fenoksi]piridin-3-il}bifenil-4-karboksamida,
N-{6-[2-fluoro-4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamida,
2-fluoro-N-{6-[2-fluoro-4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamida,
2,3,4-trifluoro-N-{6-[2-fluoro-4-(metflamino)fenoksi]piridin-3-il}benzamida,
N-{6-[2-metil-4-(metilamino)fenoksi]piridin-3-il}-4-fenoksibenzamida,
N-{6-[2-metil-4-(metilamino)fenoksi]piridin-3-il}bifenil-4-karboksamida,
N-{6-[2-metil-4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamida,
2-fluoro-N-{6-[2-metil-4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamida,
N-{6-[4-(metilamino)fenoksi]piridin-3-il}-4-fenoksibenzamida,
N-{6-[4-(metilamino)fenoksi]piridin-3-il}bifenil-4-karboksamida,
N-{6-[2-metoksi-4-(metiiamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamida,
N-{6-[2-metoksi-4-(metilamino)fenoksi]piridin-3-il}-4-fenoksibenzamida,
N-{6-[2-metoksi-4-(metilamino)fenoksi]piridin-3-il}bifenil-4-karboksamida,
2-fluoro-N-{6-[2-metoksi-4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamida,
2,3,4-trifluoro-N-{6-[2-metoksi-4-(metilamino)fenoksi]piridin-3-il}benzamida,
2,3,4-trifluoro-N-{6-[2-metil-4-(metilamino)fenoksi]piridin-3-il}benzamida,
N-{6-[4-(metiiamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamida,
2-fluoro-N-{6-[4-(metilamino)fenoksi]piridin-3-il}-4-(triftuorometil)benzamida,
2,3,4-trifluoro-N-{6-[4-(metilamino)fenoksi]piridin-3-il}benzamida,
N-{6-[2-fluoro-4-(metilamino)fenoksi]piridin-3-il}-4-fenoksibenzamid hidroklorida,
2-fluoro-N-{6-[2-fluoro-4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamid hidroklorida,
2,3,4-trifluoro-N-{6-[2-fluoro-4-(metilamino)fenoksi]piridin-3-il}benzamid hidroklorida,
N-{6-[2-metil-4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamid hidroklorida,
2,3,4-trifluoro-N-{6-[2-metil-4-(metilamino)fenoksi]piridin-3-il}benzamid hidroklorida,
N-{6-[2-metoksi-4-(metilamino)fenoksi]piridin-3-il}-4-fenoksibenzamid hidroklorida,
N-{6-[2-metoksi-4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamid hidroklorida,
2-fluoro-N-{6-[2-metoksi-4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamid hidroklorida,
2,3,4-trifluoro-N-{6-[2-metoksi-4-(metiiamino)fenoksi]piridin-3-il}benzamid hidroklorida,
N-{6-[4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamid hidroklorida,
2-fluoro-N-{6-[4-(metilamino)fenoksi]piridin-3-il}-4-(trifluorometil)benzamid hidroklorida, i
2,3,4-trifluoro-N- {6-[4-(metilamino)fenoksi]piridin-3-il}benzamid hidroklorida.
8. Farmaceutski pripravak, naznačen time, da sadrži spoj predstavljen općom formulom (1) ili njegovu sol u skladu s patentnim zahtjevom 1 i farmaceutski prihvatljiv nosač.
9. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time, da se koristi za sprječavanje i/ili liječenje raka.
10. Spoj predstavljen općom formulom (1) ili njegova sol u skladu s patentnim zahtjevom 1, naznačen time, da se koristi u farmaceutskom pripravku.
11. Uporaba spoja predstavljenog općom formulom (1) ili njegova sol u skladu s patentnim zahtjevom 1, naznačena time, da se koristi za proizvodnju farmaceutskog pripravka.
12. Spoj predstavljen općom formulom (1) ili njegova sol u skladu s patentnim zahtjevom 1, naznačen time, da se koristi u postupku sprječavanja i/ili liječenja raka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38939310P | 2010-10-04 | 2010-10-04 | |
| EP20110773326 EP2624833B1 (en) | 2010-10-04 | 2011-10-03 | 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer |
| PCT/JP2011/073165 WO2012046825A1 (en) | 2010-10-04 | 2011-10-03 | 4- (methylaminophenoxy) pyrdin- 3 - yl - benzamide derivatives for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20141237T1 true HRP20141237T1 (hr) | 2015-02-13 |
Family
ID=44872549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141237AT HRP20141237T1 (hr) | 2010-10-04 | 2011-10-03 | Derivati 4-(metilaminofenoksi)pirdin-3-ilbenzamida za lijeäśenje raka |
Country Status (29)
| Country | Link |
|---|---|
| US (8) | US8946437B2 (hr) |
| EP (1) | EP2624833B1 (hr) |
| JP (1) | JP5715690B2 (hr) |
| KR (1) | KR101797797B1 (hr) |
| CN (1) | CN103189061B (hr) |
| AR (1) | AR083287A1 (hr) |
| AU (1) | AU2011313236B2 (hr) |
| BR (1) | BR112013007841B1 (hr) |
| CA (1) | CA2813153C (hr) |
| CO (1) | CO6660459A2 (hr) |
| DK (1) | DK2624833T3 (hr) |
| EA (1) | EA021627B1 (hr) |
| ES (1) | ES2526574T3 (hr) |
| HR (1) | HRP20141237T1 (hr) |
| IL (1) | IL225520A (hr) |
| MX (1) | MX2013003589A (hr) |
| MY (1) | MY157563A (hr) |
| NZ (1) | NZ609151A (hr) |
| PH (1) | PH12013500605B1 (hr) |
| PL (1) | PL2624833T3 (hr) |
| PT (1) | PT2624833E (hr) |
| RS (1) | RS53749B1 (hr) |
| SG (1) | SG189146A1 (hr) |
| SI (1) | SI2624833T1 (hr) |
| SM (1) | SMT201500056B (hr) |
| TW (1) | TWI526431B (hr) |
| UA (1) | UA110037C2 (hr) |
| WO (1) | WO2012046825A1 (hr) |
| ZA (1) | ZA201302332B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013500605B1 (en) * | 2010-10-04 | 2018-07-04 | Otsuka Pharma Co Ltd | 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer |
| JP6066806B2 (ja) * | 2012-04-03 | 2017-01-25 | 大塚製薬株式会社 | 医薬 |
| SG11202108523UA (en) * | 2019-03-25 | 2021-09-29 | Otsuka Pharma Co Ltd | Antitumor composition |
| CN118005541B (zh) * | 2023-12-13 | 2025-05-30 | 张家港格瑞特化学有限公司 | 一种双牛磺酸盐及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
| ZA200700811B (en) | 2004-08-06 | 2008-10-29 | Otsuka Pharma Co Ltd | Aromatic compound |
| CN101321529B (zh) | 2005-12-05 | 2012-09-05 | 大塚制药株式会社 | 作为抗肿瘤剂的二芳基醚衍生物 |
| UA95978C2 (ru) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
| PH12013500605B1 (en) * | 2010-10-04 | 2018-07-04 | Otsuka Pharma Co Ltd | 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer |
| SG11202108523UA (en) * | 2019-03-25 | 2021-09-29 | Otsuka Pharma Co Ltd | Antitumor composition |
-
2011
- 2011-10-03 PH PH1/2013/500605A patent/PH12013500605B1/en unknown
- 2011-10-03 EP EP20110773326 patent/EP2624833B1/en active Active
- 2011-10-03 KR KR1020137008052A patent/KR101797797B1/ko active Active
- 2011-10-03 DK DK11773326T patent/DK2624833T3/en active
- 2011-10-03 US US13/877,276 patent/US8946437B2/en active Active
- 2011-10-03 TW TW100135750A patent/TWI526431B/zh active
- 2011-10-03 WO PCT/JP2011/073165 patent/WO2012046825A1/en not_active Ceased
- 2011-10-03 ES ES11773326.1T patent/ES2526574T3/es active Active
- 2011-10-03 HR HRP20141237AT patent/HRP20141237T1/hr unknown
- 2011-10-03 IL IL225520A patent/IL225520A/en active IP Right Grant
- 2011-10-03 MY MYPI2013001147A patent/MY157563A/en unknown
- 2011-10-03 JP JP2013515439A patent/JP5715690B2/ja active Active
- 2011-10-03 SG SG2013023148A patent/SG189146A1/en unknown
- 2011-10-03 EA EA201390323A patent/EA021627B1/ru unknown
- 2011-10-03 PT PT11773326T patent/PT2624833E/pt unknown
- 2011-10-03 MX MX2013003589A patent/MX2013003589A/es active IP Right Grant
- 2011-10-03 PL PL11773326T patent/PL2624833T3/pl unknown
- 2011-10-03 AR ARP110103657 patent/AR083287A1/es unknown
- 2011-10-03 NZ NZ60915111A patent/NZ609151A/en unknown
- 2011-10-03 CN CN201180047707.2A patent/CN103189061B/zh active Active
- 2011-10-03 UA UAA201303865A patent/UA110037C2/uk unknown
- 2011-10-03 RS RS20150024A patent/RS53749B1/sr unknown
- 2011-10-03 CA CA2813153A patent/CA2813153C/en active Active
- 2011-10-03 BR BR112013007841-3A patent/BR112013007841B1/pt active IP Right Grant
- 2011-10-03 AU AU2011313236A patent/AU2011313236B2/en active Active
- 2011-10-03 SI SI201130409T patent/SI2624833T1/sl unknown
-
2013
- 2013-03-28 ZA ZA2013/02332A patent/ZA201302332B/en unknown
- 2013-04-16 CO CO13097703A patent/CO6660459A2/es unknown
-
2014
- 2014-12-17 US US14/574,102 patent/US20150105432A1/en not_active Abandoned
-
2015
- 2015-03-09 SM SM201500056T patent/SMT201500056B/xx unknown
-
2016
- 2016-11-28 US US15/362,561 patent/US20170298023A1/en not_active Abandoned
-
2018
- 2018-05-02 US US15/969,690 patent/US20180265471A1/en not_active Abandoned
-
2019
- 2019-06-13 US US16/440,924 patent/US20200031773A1/en not_active Abandoned
-
2020
- 2020-09-30 US US17/039,731 patent/US20210017134A1/en not_active Abandoned
-
2022
- 2022-12-30 US US18/148,672 patent/US20230139808A1/en not_active Abandoned
-
2024
- 2024-08-26 US US18/814,803 patent/US20240417376A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012255759C1 (en) | Kinase inhibitors | |
| HRP20181169T1 (hr) | Predlijekovi fumarata i njihova upotreba u liječenju različitih bolesti | |
| NZ607638A (en) | Novel compounds and compositions for the inhibition of nampt | |
| MY157073A (en) | Conversion method | |
| HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
| NZ590784A (en) | Pyrazolopyridine kinase inhibitors | |
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| PE20120171A1 (es) | Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acidos aminonicotinico como inhibidores de dhodh | |
| EA036672B8 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| HK1202541A1 (en) | 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors | |
| NZ605627A (en) | Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase | |
| MY209129A (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| HRP20191826T4 (hr) | Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta | |
| MD20140084A2 (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| HRP20201985T1 (hr) | Piridonski spoj kao c-met inhibitor | |
| HRP20161498T1 (hr) | Inhibitori kinaza i njihova upotreba u liječenju raka | |
| PH12015501567A1 (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| PH12016500359A1 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
| JP2014503525A5 (hr) | ||
| WO2007122634A3 (en) | Pyrimidinediones as tyrosine kinase inhibitors | |
| HRP20141237T1 (hr) | Derivati 4-(metilaminofenoksi)pirdin-3-ilbenzamida za lijeäśenje raka | |
| RU2019142472A (ru) | Глюкуронидные пролекарства ингибиторов янус-киназы | |
| MX344276B (es) | Compuesto de piperidina novedoso o sal del mismo. | |
| MA32460B1 (fr) | Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases |